Exclusive U.S. licensing deal aims to reshape colorectal cancer screening landscape
Exact Sciences secured exclusive U.S. commercialization rights to Freenome’s blood-based colorectal cancer screening test through a licensing agreement worth up to $885 million in milestones.
The partnership combines Exact Sciences’ established commercial presence in cancer screening with Freenome’s innovative liquid biopsy technology, potentially creating a more convenient alternative to existing screening methods.
Market Disruption Potential: Blood-based screening could significantly increase colorectal cancer screening compliance by offering a simpler alternative to colonoscopy or stool-based tests. Freenome retains rights for multi-cancer applications, allowing parallel development of broader screening panels.
Exact Sciences will accelerate the test’s commercialization using its established relationships with healthcare providers and payers, while Freenome focuses on expanding the platform to additional cancer types.
